Clinical Trial Update: A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. [Phase 2]

View source ↗

Summary

A Phase 2 study assessed four doses of BI 1744 CL delivered via the Respimat inhaler in patients with asthma; the trial has completed and results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-05